Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Intravenous bisphosphonates

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population
Abstract Objectives: Skeletal-related events (SREs), i.e. pathologic fractures, spinal cord compression, surgery and radiation to… Expand
Is this relevant?
2019
2019
Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States
Abstract Background Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal… Expand
Is this relevant?
Review
2019
Review
2019
Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
INTRODUCTION Intravenous bisphosphonates (IV BP) have been used to treat children with osteoporosis for many years. Favorable… Expand
Is this relevant?
2015
2015
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
The renal status of patients with bone metastases secondary to solid tumors and their treatment with nephrotoxic agents is not… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
Oxidative stress in bisphosphonate-related osteonecrosis of the jaws.
OBJECTIVES To analyze whether oxidative stress (OS) changes are present in patients with bisphosphonate-related osteonecrosis of… Expand
Is this relevant?
2014
2014
Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US
PurposeThree bone-targeted agents (BTAs) are approved in the USA for prevention of bone complications among solid tumor patients… Expand
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2013
2013
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer
PurposeCancer patients with bone metastases (BMets) are predisposed to skeletal complications. Bone-targeted therapies such as… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
PURPOSE Atypical femur fractures represent a potential complication of chronic oral bisphosphonate therapy in women with… Expand
Is this relevant?
2011
2011
Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
PURPOSE The etiology of osteonecrosis of the jaw is poorly understood, but preferential mandibular uptake of intravenous… Expand
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
PURPOSE Denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor-kappaB ligand, suppresses bone… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE